UNITY Biotechnology
12 followers
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.
Org chart
Anirvan Ghosh
Collapse
Gilmore O’Neill
President & CEO, Editas Medicine
Przemyslaw (Mike) Sapieha
Chief Scientific Advisor
Lynne Sullivan
CFO & Head of Corporate Development
Alicia Tozier
Chief Strategy Officer
Alexander Nguyen
General Counsel
Sara Huang
VP, Clinical Operations
Mike Sapieha
Chief Scientist
David Buttaro
Executive Director, HR & Operations
Qifeng Xue
Executive Director, Analytical Development and Quality Control
Robert B. Bhisitkul
Senior Clinical Advisor
